Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study

Contraception

Volumn 60, Issue 5, 1999, Pages 269-274

  Endrikat, J ^a   Dusterberg B ^a   Ruebig, A ^a   Gerlinger, C ^a   Strowitzki, T ^b  

^a BAYER PHARMA AG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cycle control; Desogestrel; Ethinyl estradiol; Gestodene; Oral contraceptives

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; LOW DOSE ORAL CONTRACEPTIVE;

ADOLESCENT; ADULT; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DYSMENORRHEA; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MASTALGIA; MENSTRUAL CYCLE; MULTICENTER STUDY; NAUSEA; NORMAL HUMAN; ORAL CONTRACEPTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SPOTTING;

AUSTRIA; COMPARATIVE STUDIES; CONTRACEPTION; CONTRACEPTIVE AGENTS; CONTRACEPTIVE AGENTS, ESTROGEN; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE AGENTS, PROGESTIN; CONTRACEPTIVE EFFECTIVENESS; CONTRACEPTIVE METHODS; CONTRACEPTIVE USAGE; DESOGESTREL; DEVELOPED COUNTRIES; ETHINYL ESTRADIOL; EUROPE; FAMILY PLANNING; FRANCE; GESTODENE; ITALY; MEDITERRANEAN COUNTRIES; METHOD ACCEPTABILITY; NETHERLANDS; NORTHERN EUROPE; ORAL CONTRACEPTIVES; RESEARCH METHODOLOGY; RESEARCH REPORT; SOUTHERN EUROPE; STUDIES; SWITZERLAND; UNITED KINGDOM; WESTERN EUROPE;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, COMBINED; DESOGESTREL; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; NORPREGNENES; PREGNANCY; PROGESTERONE CONGENERS; PROSPECTIVE STUDIES; UTERINE HEMORRHAGE;

EID: 0033370489     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(99)00097-9     Document Type: Article

References (8)

1. Rosenberg M.J., Waugh M.S., Meehan T.E. Use and misuse of oral contraceptives risk indications for poor pill-taking and discontinuation . Contraception. 51:1995;283-288.
2. Rosenberg M.J., Long S.C. Oral contraceptives and cycle control a critical review of the literature . Adv Contracept. 8:(suppl 1):1992;35-45.
3. Rosenberg M.J., Waugh M.S., Higgins J.E. The effect of desogestrel, gestodene and other factors on spotting and bleeding. Contraception. 53:1996;85-90.
4. Back DJ. Bioavailability of the new generation oral contraceptives: what should the GP know? Medical Dialogue 1993; no. 388.
5. Endrikat J, Jaques M-A, Mayerhofer M, et al. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinyl estradiol/75 μg gestodene and 20 μg ethinyl estradiol/150 μg desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995;52:229-3.
6. Düsterberg B., Ellman H., Müller U., et al. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endocrinol. 10:1996;33-39.
7. Gast J., Grubb G. A review of cycle control with a low-dose oral contraceptive containing 75 μg gestodene and 20 μg ethiniyl estradiol. Gynecol Endocrinol. 12:(suppl 3):1998;31-37.
8. Clinical comparison of monophasic oral contraceptive preparations of gestodene/ethinyl estradiol and desogestrel/ethinyl estradiol. Contraception. 50:1994;201-214.